Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus

Ousseny Zerbo; Joan Bartlett; Bruce Fireman; Kristin Goddard; Jonathan Duffy; Jason Glanz; Allison L Naleway; James G Donahue; Tara C Anderson; Nicola P Klein

doi:10.1001/jamanetworkopen.2025.14615

Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus

JAMA Netw Open. 2025 Jun 2;8(6):e2514615. doi: 10.1001/jamanetworkopen.2025.14615.

Authors

Affiliations

¹ Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California.
² US Centers for Disease Control and Prevention, Atlanta, Georgia.
³ Institute for Health Research, Kaiser Permanente Colorado, Denver, Colorado.
⁴ Kaiser Permanente Center for Health Research, Portland, Oregon.
⁵ Marshfield Clinic Research Institute, Marshfield, Wisconsin.

No abstract available

Plain language summary

This cohort study uses health plan data to investigate whether recombinant zoster vaccination is associated with a reduced risk of postherpetic neuralgia or zoster ophthalmicus.